Cholestene, a dietary supplement marketed for cholesterol management, has been found to contain a hidden drug ingredient, according to the Food and Drug Administration.
HOPE-3 was designed to assess if reducing BP and/or LDL-C would reduce cardiovascular events in study participants at intermediate risk with no prior cardiovascular events.
Investigators report results from MAESTRO-NAFLD-1, a phase 3, randomized, double-blind, placebo-controlled trial evaluating the effect of treatment with resmetirom in patients with hypothyroidism and nonalcoholic steatohepatitis.
This study aimed to assess the effects of the various elements of metabolic syndrome on carotid plaque destabilization.
Omega-3 fatty acids, including eicosapentaenoic acid (EPA) and docosehexaenoic acid (DHA), have been found to be associated with cardiovascular health benefits.
Comparative chart of single and combination treatment options indicating which lipids can be targeted for dyslipidemias.
Findings of the review showed that continuous insulin infusion, coupled with standard oral lipid lowering therapies, successfully treated the hypertriglyceridemia.
Researchers conducted a patient-level pooled analysis from phase 3 trials of inclisiran in patients with familial hypercholesterolemia or ASCVD.
Observational studies using Mendelian randomization have demonstrated a causal relationship between normal range thyroid stimulating hormone (TSH) levels and blood lipids. In this featured study, researchers attempt to show a causal relationship between thyroid function and lipids.
Study authors performed a retrospective review of a thyroid cancer cohort to evaluate the association between metabolic health and severity of thyroid cancer.
A team of investigators conducted a large retrospective, cohort study to assess whether a longitudinal link exists between H pylori infection and the risk of developing dyslipidemia.